We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


FDA will use GeneGo's MetaCore

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

GeneGo, Inc. has announced that the U.S. Food and Drug Administration (FDA) have licensed MetaCore for "OMIC's" research and reviewing of genomics data. 

GeneGo and the FDA will also integrate MetaCore with ArrayTrack and make it available for FDA Researchers.

The MetaCore platform is designed to allow scientists to concurrently visualize, map and network multiple types of data including gene expression, SiRNAi, proteomic, metabolomic, SAGE and SNP data, both from pre-clinical discovery and clinical studies.

“High throughput (HT) experimentation is increasingly important for life science research, and HT data is now included in many new drug applications submissions,”  said Dr Tatiana Nikolskaya, founder and CSO of GeneGo Inc. 

“The analysis of such complex datasets requires novel systems biology tools, such as MetaCore.”

“One important issue in FDA submissions is compatibility and cross-referencing of multiple types of pre-clinical and clinical data, which are collected at different times by different research groups.”

“MetaCore offers both a functional framework and analytical engine for this.”

“Working with the FDA is very important for GeneGo and we are very pleased to announce this relationship,” said Julie Bryant, Vice President of Business Development at GeneGo.

“Since MetaCore is already being applied in drug discovery by our pharmaceutical customers for a couple of years now, it is logical that it will be also used on the regulatory side as well.”